• Cochlear remains the global leader in implantable hearing solutions
• Investing in R&D and innovation to enhance hearing outcomes and quality of life
• Strengthening culture, leadership development, and Board renewal

Cochlear Limited's 2025 Annual General Meeting addresses by the Chair and CEO & President provide an overview of the company's progress and key priorities. Cochlear remains the global leader in implantable hearing solutions, connecting hundreds of thousands of people to a full life of hearing. The company is committed to transforming the way people understand and treat hearing loss, and addressing the significant unmet clinical needs in hearing health. Over the past year, Cochlear has delivered solid financial outcomes and brought ground-breaking new products to market, including the Cochlear™ Nucleus® Nexa™ System, the world's first smart cochlear implant system with upgradeable firmware. The company's focus on innovation, long-term growth, and investment in its people continue to strengthen the value it delivers for stakeholders. Cochlear is also committed to environmental responsibility, with initiatives to support the sustainable use of natural resources and minimize its environmental impact. Looking ahead, the company is confident in its ability to expand within its markets, with a substantial and addressable clinical need for cochlear and acoustic implants supporting the long-term sustainable growth of the business.

Cochlear provided earnings guidance for FY26, outlining an expected increase in underlying net profit of 11-17% on FY25, up 5-11% on a comparative (cloud adjusted) basis.

Cochlear is confident in its ability to expand within its markets, with a substantial and addressable clinical need for cochlear and acoustic implants supporting the long-term sustainable growth of the business. The company remains alert to potential strain on global supply chains due to increased trade tensions, and is managing this by working closely with suppliers and carrying higher levels of inventory.